SANUWAVE Health, Inc. (SNWV)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SANUWAVE Health, Inc. (SNWV) trades at $10.21 with AI Score 32/100 (Grade D). SANUWAVE Health, Inc. is a medical device company specializing in shock wave technology for regenerative medicine. Market cap: $87.76M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for SNWV: SNWV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNWV against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SNWV: 3/7 perspectives are bearish. Dominant signal: Izzy Englander bearish.
How is this calculated? →SANUWAVE Health, Inc. (SNWV) Healthcare & Pipeline Overview
SANUWAVE Health, Inc. develops and commercializes shock wave technology for regenerative medicine, focusing on noninvasive solutions for tissue repair and regeneration. Its dermaPACE device addresses diabetic foot ulcers, positioning the company in the advanced wound care market with a focus on stimulating the body's natural healing processes.
What Is the Investment Thesis for SNWV?
SANUWAVE Health, Inc. presents a focused investment opportunity within the regenerative medicine sector, driven by its proprietary shock wave technology. The company's dermaPACE device, targeting the treatment of diabetic foot ulcers, addresses a significant unmet medical need. With a market capitalization of $87.76M and a P/E ratio of 11.29, SANUWAVE exhibits potential value. A gross margin of 75.1% indicates strong pricing power. Growth catalysts include expanding clinical applications of PACE technology and securing regulatory approvals in new markets. Potential risks include competition from established wound care companies and the need for further clinical validation. The company's beta of 1.51 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
SNWV Key Highlights
- Market Cap of $87.76M reflects the company's current valuation in the regenerative medicine market.
- P/E ratio of 11.29 suggests potential value relative to earnings.
- Gross Margin of 75.1% indicates strong pricing power and efficient cost management.
- Profit Margin of 26.8% demonstrates the company's ability to convert revenue into profit.
- Beta of 1.51 indicates higher volatility compared to the overall market.
Who Are SNWV's Competitors?
SNWV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNWV's Key Strengths?
- Proprietary shock wave technology.
- Clinical data supporting efficacy of dermaPACE.
- Focus on noninvasive regenerative medicine.
- High gross margin of 75.1%.
What Are SNWV's Weaknesses?
- Limited market presence compared to established players.
- Reliance on a few key products.
- Need for further clinical validation in new indications.
- Higher volatility compared to the market (Beta of 1.51).
What Could Drive SNWV Stock Higher?
- Potential FDA approval for new indications of dermaPACE.
- Expansion of clinical trials to demonstrate efficacy in additional wound types.
- Strategic partnerships with healthcare providers and distributors to increase market access.
What Are the Key Risks for SNWV?
- Financial-distress signal — its Altman Z-Score of -4.40 sits in the distress zone (elevated bankruptcy risk).
- Competition from established wound care companies with greater resources.
- Regulatory hurdles and delays in obtaining approvals for new products.
- Dependence on reimbursement policies for market adoption of dermaPACE.
- Negative clinical trial results impacting product efficacy claims.
What Are the Growth Opportunities for SNWV?
- Expansion of dermaPACE into new geographic markets: SANUWAVE has the opportunity to expand the dermaPACE device into new geographic markets beyond the United States. This includes targeting regions with high rates of diabetes and limited access to advanced wound care technologies. Securing regulatory approvals in Europe and Asia could significantly increase the market reach and revenue potential for dermaPACE. The global wound care market is projected to reach $22 billion by 2028.
- Development of new applications for PACE technology: SANUWAVE can leverage its Pulsed Acoustic Cellular Expression (PACE) technology to develop new applications beyond diabetic foot ulcers. This includes exploring the use of PACE in orthopedic conditions, plastic/cosmetic surgery, and cardiac conditions. Expanding the application of PACE technology could diversify the company's product portfolio and address multiple high-growth markets. The orthopedic market is projected to reach $55 billion by 2027.
- Strategic partnerships with healthcare providers and distributors: SANUWAVE can accelerate market adoption of its products through strategic partnerships with healthcare providers and distributors. Collaborating with hospitals, clinics, and wound care centers can increase access to dermaPACE and UltraMIST for patients. Partnering with established distributors can expand the company's sales network and market presence. These partnerships can drive revenue growth and market share gains.
- Clinical trials to demonstrate efficacy in additional indications: SANUWAVE should conduct additional clinical trials to demonstrate the efficacy of its products in treating various indications. This includes conducting studies to evaluate the use of dermaPACE in treating other types of chronic wounds, such as pressure ulcers and venous leg ulcers. Positive clinical trial results can support regulatory approvals and increase physician adoption of SANUWAVE's products. The chronic wound care market is projected to reach $12 billion by 2025.
- Focus on reimbursement strategies to improve access to care: SANUWAVE needs to focus on developing effective reimbursement strategies to improve patient access to its products. This includes working with insurance companies and government healthcare programs to secure coverage for dermaPACE and UltraMIST. Obtaining favorable reimbursement policies can reduce the out-of-pocket costs for patients and increase the adoption of SANUWAVE's products. The reimbursement landscape for advanced wound care therapies is constantly evolving.
What Opportunities Does SNWV Have?
- Expansion into new geographic markets.
- Development of new applications for PACE technology.
- Strategic partnerships with healthcare providers.
- Favorable reimbursement policies for advanced wound care.
What Threats Does SNWV Face?
- Competition from established wound care companies.
- Regulatory hurdles and approval processes.
- Technological advancements by competitors.
- Changes in reimbursement policies.
What Are SNWV's Competitive Advantages?
- Proprietary shock wave technology and patents.
- Clinical data supporting the efficacy of dermaPACE.
- Established relationships with key opinion leaders in wound care.
- Focus on noninvasive solutions for regenerative medicine.
What Does SNWV Do?
Founded in 2005 and headquartered in Suwanee, Georgia, SANUWAVE Health, Inc. is a shock wave technology company dedicated to researching, developing, and commercializing noninvasive, high-energy, and acoustic shock waves for regenerative medicine applications. The company's core technology leverages shockwaves to stimulate a biological response, facilitating the body's natural healing processes through tissue repair, musculoskeletal regeneration, and vascular structure improvement. SANUWAVE's lead product, dermaPACE, is designed for the treatment of diabetic foot ulcers, a significant and growing healthcare challenge. Beyond dermaPACE, the company's portfolio includes healthcare products and product candidates that activate biologic signaling and angiogenic responses, promoting new vascularization and microcirculatory enhancement to restore the body's regenerative capabilities. SANUWAVE also offers UltraMIST, a non-contact, non-thermal ultrasound therapy device for treating various types of ulcers and wounds, and orthoPACE, a system for addressing tendinopathies and fractures. The company aims to expand the application of its Pulsed Acoustic Cellular Expression (PACE) technology across wound healing, orthopedic, plastic/cosmetic, and cardiac conditions.
What Products and Services Does SNWV Offer?
- Develop and commercialize shock wave technology for regenerative medicine.
- Offer dermaPACE device for treating diabetic foot ulcers.
- Provide UltraMIST, a non-contact ultrasound therapy device for wound care.
- Offer orthoPACE system for treating tendinopathies and fractures.
- Apply Pulsed Acoustic Cellular Expression (PACE) technology in various medical fields.
- Focus on noninvasive solutions for tissue repair and regeneration.
- Activate biologic signaling and angiogenic responses for healing.
How Does SNWV Make Money?
- Develop, manufacture, and sell medical devices based on shock wave technology.
- Generate revenue through direct sales to hospitals, clinics, and wound care centers.
- Establish partnerships with distributors to expand market reach.
- Pursue reimbursement agreements with insurance companies and government healthcare programs.
What Industry Does SNWV Operate In?
SANUWAVE Health, Inc. operates within the medical device industry, specifically targeting the advanced wound care and regenerative medicine segments. The market for advanced wound care is driven by the increasing prevalence of chronic diseases like diabetes, which leads to conditions such as diabetic foot ulcers. The competitive landscape includes established players offering traditional wound care products and emerging companies developing innovative regenerative therapies. SANUWAVE's shock wave technology offers a differentiated approach to wound healing by stimulating the body's natural regenerative processes.
Who Are SNWV's Key Customers?
- Hospitals and clinics specializing in wound care.
- Wound care centers and specialists.
- Podiatrists and orthopedic surgeons.
- Patients suffering from diabetic foot ulcers and other chronic wounds.
FY2026 estForward Outlook
Wall Street analysts project SANUWAVE Health, Inc. revenue of about $51.4M for fiscal 2026, with EPS near $-0.08.
F-Score 4/9Financial Health
SANUWAVE Health, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.40 places it in the distress zone, a signal of elevated financial risk.
P/E 5.7Key Financial Metrics
Return on assets is 43.3%, showing how much profit it generates from its asset base. SNWV trades at a trailing price-to-earnings ratio of 5.69, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 17.6%, the inverse of the P/E and a quick read on earnings relative to price.
SANUWAVE Health, Inc. (SNWV) Valuation Context
Valued at $87.76M, SNWV is classified as a micro-cap stock. Relative to its peer group, SNWV's quantitative score of 32/100 is below the peer average of 69/100.
Company Profile
SANUWAVE Health, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Suwanee, US. The company is led by CEO Morgan C. Frank. SNWV has traded publicly since 2009.
SNWV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal confidence in SANUWAVE's future prospects, suggesting those closest to the company see value.
- The community seems to be buzzing about potential new applications for SANUWAVE's technology, indicating growing excitement and potential market expansion.
- There's a perception that SANUWAVE is undervalued compared to its peers, leading to speculation that it could be a strong acquisition target.
- Positive community sentiment suggests that SANUWAVE is gaining traction and mindshare, which could translate to increased investor interest.
Bear Case
- Lack of consistent news flow from the company raises concerns about transparency and potential operational challenges.
- The community is expressing worries about the company's ability to scale production to meet potential demand, hinting at possible supply chain issues.
- There's a growing narrative that SANUWAVE is overly reliant on a single product, creating vulnerability if market conditions shift.
- Bearish sentiment in the community points to skepticism about the company's long-term viability, possibly driven by past performance or market conditions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SNWV Latest News
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga · Jun 16, 2026
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Jun 16, 2026
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
SNWV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNWV.
Price Targets
Wall Street price target analysis for SNWV.
SNWV MoonshotScore
What does this score mean?
The MoonshotScore rates SNWV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest SANUWAVE Health, Inc. Analysis
Leadership: Morgan C. Frank
CEO
Morgan C. Frank serves as the CEO of SANUWAVE Health, Inc., leading the company's strategic direction and overseeing its operations. His background includes experience in managing and scaling healthcare companies, with a focus on medical devices and regenerative medicine. He is responsible for managing 46 employees. Frank's expertise lies in commercializing innovative medical technologies and driving market adoption.
Track Record: Under Morgan C. Frank's leadership, SANUWAVE Health, Inc. has focused on expanding the clinical applications of its PACE technology and securing regulatory approvals for its products. He has overseen the commercialization of dermaPACE and UltraMIST, targeting the treatment of diabetic foot ulcers and other chronic wounds. His strategic decisions have aimed to position SANUWAVE as a leader in noninvasive regenerative medicine.
SNWV Healthcare Stock FAQ
What does SANUWAVE Health, Inc. do?
SANUWAVE Health, Inc. is a medical device company that develops and commercializes shock wave technology for regenerative medicine. The company's primary focus is on noninvasive solutions for tissue repair and regeneration, with its lead product, dermaPACE, targeting the treatment of diabetic foot ulcers. SANUWAVE's technology leverages shockwaves to stimulate a biological response, promoting the body's natural healing processes. The company also offers UltraMIST, a non-contact ultrasound therapy device for wound care, and orthoPACE, a system for treating tendinopathies and fractures.
What do analysts say about SNWV stock?
Analyst coverage of SANUWAVE Health, Inc. is limited, but existing reports suggest a focus on the company's growth potential within the regenerative medicine sector. Key valuation metrics include market capitalization, P/E ratio, and gross margin. Growth considerations include the expansion of dermaPACE into new markets, the development of new applications for PACE technology, and the securing of favorable reimbursement policies. Analysts also monitor the company's clinical trial results and regulatory approvals.
What are the main risks for SNWV?
The main risks for SANUWAVE Health, Inc. include competition from established wound care companies, regulatory hurdles and approval processes, dependence on reimbursement policies, and potential negative clinical trial results. The company faces competition from larger companies with greater resources and market presence. Regulatory delays or unfavorable reimbursement decisions could impact the adoption of SANUWAVE's products. Negative clinical trial results could undermine the efficacy claims of its products and reduce market demand.
What are the key factors to evaluate for SNWV?
SANUWAVE Health, Inc. (SNWV) holds an AI score of 32/100 (low). Not financial advice.
How frequently does SNWV data refresh on this page?
SNWV prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SNWV's recent stock price performance?
SANUWAVE Health, Inc. (SNWV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary shock wave technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNWV overvalued or undervalued right now?
Valuing SANUWAVE Health, Inc. (SNWV) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SNWV?
Before investing in SANUWAVE Health, Inc. (SNWV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for SNWV.
- Market data projections are estimates and subject to change.